AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15226332 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (AC)
Number of subjects: 219
Study 15226332 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant chemotherapy (no AC)
Number of subjects: 219
Study 11476129 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine (mean daily dose, 128.4 mg; range, 100‐150 mg)
Number of subjects: 36
Study 11476129 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (mean daily dose, 1.3 mg; range, 1‐1.5 mg)
Number of subjects: 36
Study 11476129 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 9246021 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 600 mg
Number of subjects: 0
Study 9246021 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9246021 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone
Number of subjects: 0
Study 8489062 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual midazolam (0.2 mg/kg)
Number of subjects: 93
Study 8489062 — intervention group
Group type: COMPARATOR
Intervention: Intranasal midazolam (0.2 mg/kg)
Number of subjects: 93
Study 8489062 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual flavored midazolam
Number of subjects: 93
Study 8489062 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual and intranasal midazolam
Number of subjects: 93
Study 3687999 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet
Number of subjects: 24
Study 3687999 — intervention group
Group type: EXPERIMENTAL
Intervention: Suspension
Number of subjects: 24
Study 3687999 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet and Suspension
Number of subjects: 24
Study 31765759 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication coaching intervention
Number of subjects: 22
Study 31765759 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 22
Study 28940805 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone-on-release pack containing a single 'rescue' injection of naloxone
Number of subjects: 1685
Study 28940805 — intervention group
Group type: COMPARATOR
Intervention: Control pack with no naloxone syringe
Number of subjects: 1685
Study 29949331 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral De Qi
Number of subjects: 501
Study 29949331 — intervention group
Group type: COMPARATOR
Intervention: Unilateral De Qi
Number of subjects: 501
Study 25270084 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial dermis (Matriderm) applied in combination with a split-thickness autograft
Number of subjects: 40
Study 22921098 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar diathermia
Number of subjects: 50
Study 22921098 — intervention group
Group type: COMPARATOR
Intervention: Monopolar diathermia
Number of subjects: 50
Study 22921098 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravasation of distension fluid > 1000 mL
Number of subjects: 50
Study 20528997 — intervention group
Group type: EXPERIMENTAL
Intervention: Multipolar circular ablation catheter (PVAC)
Number of subjects: 102
Study 20528997 — intervention group
Group type: COMPARATOR
Intervention: Point-by-point ablation using irrigated-tip catheter and CARTO mapping system (CARTO)
Number of subjects: 102
Study 18672538 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir (LPV/r) monotherapy
Number of subjects: 0
Study 18672538 — intervention group
Group type: COMPARATOR
Intervention: Standard triple-drug therapy (LPV/r plus zidovudine/lamivudine)
Number of subjects: 0
Study 16239890 — intervention group
Group type: EXPERIMENTAL
Intervention: Early isolated lumbar extension exercise program
Number of subjects: 75
Study 16239890 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 75
Study 12586507 — intervention group
Group type: EXPERIMENTAL
Intervention: Colon-targeted tablets of mebendazole (50 mg)
Number of subjects: 6
Study 12586507 — intervention group
Group type: COMPARATOR
Intervention: Immediate release tablets of mebendazole (50 mg)
Number of subjects: 6
Study 10553834 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% B
Number of subjects: 62
Study 10553834 — intervention group
Group type: COMPARATOR
Intervention: 0.1% B
Number of subjects: 62
Study 10553834 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 10165115 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive videoteleconferencing
Number of subjects: 40
Study 10165115 — intervention group
Group type: COMPARATOR
Intervention: On-site classroom methods
Number of subjects: 40
Study 1387246 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 0.04 mg/kg to 0.35 mg/kg
Number of subjects: 89
Study 1387246 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 0.01 mg/kg to 0.48 mg/kg
Number of subjects: 89
Study 1387246 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron 0.15 mg/kg
Number of subjects: 89
Study 3863469 — intervention group
Group type: EXPERIMENTAL
Intervention: Mianserin 20-60 mg
Number of subjects: 50
Study 3863469 — intervention group
Group type: COMPARATOR
Intervention: Imipramine 75-150 mg
Number of subjects: 50
Study 31353666 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacha inchi oil (SIO)
Number of subjects: 42
Study 28541822 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality salience
Number of subjects: 0
Study 28541822 — intervention group
Group type: EXPERIMENTAL
Intervention: Materialism
Number of subjects: 0
Study 26666876 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg for 18 months
Number of subjects: 0
Study 26666876 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 18 months
Number of subjects: 0
Study 25636415 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 kVp cerebral CTA with SAFIRE reconstruction (S1-S5)
Number of subjects: 100
Study 25636415 — intervention group
Group type: COMPARATOR
Intervention: 120 kVp cerebral CTA with filtered back projection (FBP) reconstruction
Number of subjects: 100
Study 24309414 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive supervision intervention
Number of subjects: 0
Study 20940645 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) warm-up consisting of intermittent bouts of 30 seconds of isometric squats for a total of 5 minutes.
Number of subjects: 27
Study 20940645 — intervention group
Group type: COMPARATOR
Intervention: Cycle ergometry (CE) warm-up consisting of 5 minutes of pedaling at 65‐85% of age‐predicted max heart rate.
Number of subjects: 27
Study 18785581 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (IT) group
Number of subjects: 36
Study 18785581 — intervention group
Group type: COMPARATOR
Intervention: Routine therapy (RT) group
Number of subjects: 36
Study 16415711 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine orally disintegrating tablets (ODT) 45 mg OD
Number of subjects: 0
Study 16415711 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine ODT
Number of subjects: 0
Study 16415711 — intervention group
Group type: COMPARATOR
Intervention: Venlafaxine extended-release (XR) 225 mg OD
Number of subjects: 0
Study 14986846 — intervention group
Group type: EXPERIMENTAL
Intervention: Startle probe modulation during affective picture viewing
Number of subjects: 0
Study 14986846 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluative judgments and autonomic reaction to affective stimuli
Number of subjects: 0
Study 10656949 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified mirrored-box simulator
Number of subjects: 22
Study 10656949 — intervention group
Group type: COMPARATOR
Intervention: Video-laparoscopic cart system
Number of subjects: 22
Study 8867517 — intervention group
Group type: EXPERIMENTAL
Intervention: Diethylpropion 25 mg
Number of subjects: 46
Study 8867517 — intervention group
Group type: EXPERIMENTAL
Intervention: Diethylpropion 50 mg
Number of subjects: 46
Study 8867517 — intervention group
Group type: EXPERIMENTAL
Intervention: Diethylpropion 75 mg
Number of subjects: 46
Study 8867517 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 1322060 — intervention group
Group type: EXPERIMENTAL
Intervention: LTC4 at 0.063 pmol.kg‐1.min‐1
Number of subjects: 4
Study 1322060 — intervention group
Group type: EXPERIMENTAL
Intervention: LTC4 at 0.32 pmol.kg‐1.min‐1
Number of subjects: 4
Study 1322060 — intervention group
Group type: EXPERIMENTAL
Intervention: LTC4 at 1.6 pmol.kg‐1.min‐1
Number of subjects: 4
Study 1322060 — intervention group
Group type: EXPERIMENTAL
Intervention: LTC4 at 2.9 pmol.kg‐1.min‐1
Number of subjects: 4
Study 1322060 — intervention group
Group type: COMPARATOR
Intervention: Vehicle alone (control)
Number of subjects: 4
Study 6387569 — intervention group
Group type: COMPARATOR
Intervention: Argon laser
Number of subjects: 20
Study 6387569 — intervention group
Group type: EXPERIMENTAL
Intervention: Neodymium:YAG laser
Number of subjects: 20
Study 6387569 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of both lasers
Number of subjects: 20
Study 30885718 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher serum adiponectin levels in women
Number of subjects: 112
Study 30885718 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher serum adiponectin levels in men
Number of subjects: 112
Study 30885718 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive function in men
Number of subjects: 112
Study 30885718 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety in women
Number of subjects: 112
Study 30885718 — intervention group
Group type: COMPARATOR
Intervention: Frail men
Number of subjects: 112
Study 30885718 — intervention group
Group type: EXPERIMENTAL
Intervention: Lean mass and anxiety in women
Number of subjects: 112
Study 30885718 — intervention group
Group type: EXPERIMENTAL
Intervention: Montreal Cognitive Assessment (MOCA) test in men
Number of subjects: 112
Study 29125715 — intervention group
Group type: EXPERIMENTAL
Intervention: SYM-1219 in applesauce (fasted)
Number of subjects: 48
Study 29125715 — intervention group
Group type: EXPERIMENTAL
Intervention: SYM-1219 in applesauce (fed)
Number of subjects: 48
Study 29125715 — intervention group
Group type: EXPERIMENTAL
Intervention: SYM-1219 in pudding and yogurt (fasted)
Number of subjects: 48
Study 29125715 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 48
Study 26562034 — intervention group
Group type: EXPERIMENTAL
Intervention: Homoarginine concentrations measured using liquid chromatography‐tandem mass spectrometry
Number of subjects: 786
Study 25223728 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 22
Study 25223728 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 22533981 — intervention group
Group type: COMPARATOR
Intervention: ONO‐5334 30 mg
Number of subjects: 52
Study 22533981 — intervention group
Group type: COMPARATOR
Intervention: ONO‐5334 100 mg
Number of subjects: 52
Study 22533981 — intervention group
Group type: COMPARATOR
Intervention: ONO‐5334 300 mg
Number of subjects: 52
Study 22533981 — intervention group
Group type: COMPARATOR
Intervention: ONO‐5334 600 mg
Number of subjects: 52
Study 19171571 — intervention group
Group type: EXPERIMENTAL
Intervention: Family/adolescent‐centered advance care planning sessions (3 sessions of 60-90 minutes each)
Number of subjects: 38
Study 19171571 — intervention group
Group type: COMPARATOR
Intervention: Control group received developmental history, safety tips, and future plans
Number of subjects: 38
Study 17602135 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated retrieval of target means (three or nine times)
Number of subjects: 0
Study 17602135 — intervention group
Group type: EXPERIMENTAL
Intervention: Means-recognition task
Number of subjects: 0
Study 17602135 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-means verification task
Number of subjects: 0
Study 15235912 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulus onset asynchrony (SOA) manipulations (50, 100, 200, 400, 800 ms)
Number of subjects: 0
Study 15235912 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-stimulus interval (ISI) manipulations (0, 50, 100, 150, 200, 300, 350, 400, 500, 600, 700, and 750 ms)
Number of subjects: 0
Study 15235912 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatial configuration of cues and targets
Number of subjects: 0
Study 11873074 — intervention group
Group type: EXPERIMENTAL
Intervention: High-titered ALVAC-HIV vCP205 vaccine
Number of subjects: 150
Study 10094379 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe pre-eclampsia
Number of subjects: 73
Study 10094379 — intervention group
Group type: COMPARATOR
Intervention: Uncomplicated pregnancy
Number of subjects: 73
Study 10094379 — intervention group
Group type: COMPARATOR
Intervention: Non-pregnant women
Number of subjects: 73
Study 7789354 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain-framed message (emphasizing benefits of obtaining mammography)
Number of subjects: 133
Study 7789354 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss-framed message (emphasizing risks of not obtaining mammography)
Number of subjects: 133
Study 7789354 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned, but implied as gain-framed)
Number of subjects: 133
Study 1987388 — intervention group
Group type: EXPERIMENTAL
Intervention: Ringed polytetrafluoroethylene grafts
Number of subjects: 122
Study 1987388 — intervention group
Group type: COMPARATOR
Intervention: Nonringed polytetrafluoroethylene grafts
Number of subjects: 122
Study 1987388 — intervention group
Group type: EXPERIMENTAL
Intervention: Ringed above-knee polytetrafluoroethylene grafts
Number of subjects: 122
Study 1987388 — intervention group
Group type: COMPARATOR
Intervention: Nonringed above-knee polytetrafluoroethylene grafts
Number of subjects: 122
Study 1987388 — intervention group
Group type: EXPERIMENTAL
Intervention: Ringed below-knee polytetrafluoroethylene grafts
Number of subjects: 122
Study 1987388 — intervention group
Group type: COMPARATOR
Intervention: Nonringed below-knee polytetrafluoroethylene grafts
Number of subjects: 122
Study 6633272 — intervention group
Group type: EXPERIMENTAL
Intervention: Org OD 14 (2.5 mg daily for 4 months)
Number of subjects: 29
Study 6633272 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1 tablet daily for 4 months)
Number of subjects: 29
Study 6633272 — intervention group
Group type: EXPERIMENTAL
Intervention: Org OD 14 and lynestrenol (1 mg daily during days 91-100)
Number of subjects: 29
Study 6633272 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal bleeding after cessation of treatment
Number of subjects: 29
Study 31033162 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard skin care regimen (Group A)
Number of subjects: 20
Study 31033162 — intervention group
Group type: EXPERIMENTAL
Intervention: Robust skin care regimen including chemical peels and antioxidant formulations (Group B)
Number of subjects: 20
Study 30028657 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate 1,000 mg daily and prednisone 5 mg twice daily with enzalutamide
Number of subjects: 251
Study 30028657 — intervention group
Group type: COMPARATOR
Intervention: Placebo with enzalutamide
Number of subjects: 251
Study 27265347 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 (40 mg, 50 mg, or 60 mg according to body-surface area, orally administered twice a day for 28 days followed by a 14 day rest, every 6 weeks for up to four cycles)
Number of subjects: 385
Study 27265347 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine (1000 mg/m2, intravenously administered on days 1, 8, and 15, every 4 weeks for up to six cycles)
Number of subjects: 385
Study 27265347 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1
Number of subjects: 385
Study 24752942 — intervention group
Group type: EXPERIMENTAL
Intervention: Supported employment intervention
Number of subjects: 0
Study 23216901 — intervention group
Group type: EXPERIMENTAL
Intervention: Near-total thyroidectomy leaving bilateral remnants of ≤ 1g on each side
Number of subjects: 0
Study 23216901 — intervention group
Group type: COMPARATOR
Intervention: Total thyroidectomy
Number of subjects: 0
Study 23216901 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 0
Study 20354539 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery (SRS)
Number of subjects: 0
Study 20354539 — intervention group
Group type: COMPARATOR
Intervention: Stereotactic radiosurgery (SRS) with whole-brain radiation therapy (WBRT)
Number of subjects: 0
Study 18228689 — intervention group
Group type: EXPERIMENTAL
Intervention: New treatments for orphan diseases
Number of subjects: 0
Study 18228689 — intervention group
Group type: COMPARATOR
Intervention: Randomized controlled trials
Number of subjects: 0
Study 18228689 — intervention group
Group type: COMPARATOR
Intervention: Single primary end-point
Number of subjects: 0
Study 18228689 — intervention group
Group type: COMPARATOR
Intervention: Statistically significant and clinically relevant efficiency
Number of subjects: 0
Study 15012921 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic obstructive pulmonary disease (COPD)
Number of subjects: 6669
Study 15012921 — intervention group
Group type: COMPARATOR
Intervention: No chronic obstructive pulmonary disease (Control)
Number of subjects: 6669
Study 12468561 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg ascorbic acid daily by mouth
Number of subjects: 30
Study 12468561 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 9709941 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral magnesium (15 mmol Mg) supplementation
Number of subjects: 12
Study 7638913 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic laparoscopy
Number of subjects: 60
Study 7638913 — intervention group
Group type: COMPARATOR
Intervention: Immediate appendicectomy
Number of subjects: 60
Study 2122926 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (mean daily dose, 293 mg)
Number of subjects: 63
Study 2122926 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (mean daily dose, 350 mg)
Number of subjects: 63
Study 2122926 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (mean daily dose, 79 mg)
Number of subjects: 63
Study 2122926 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 393644 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum-cholesterol-lowering (SCL) diet, low in saturated fats and cholesterol, high in polyunsaturated fats; duration: 6 years (initial period)
Number of subjects: 0
Study 393644 — intervention group
Group type: COMPARATOR
Intervention: Normal hospital diet; duration: 6 years (initial period)
Number of subjects: 0
Study 30793165 — intervention group
Group type: EXPERIMENTAL
Intervention: Concept IMF with large, milk phospholipid-coated lipid droplets (n=115)
Number of subjects: 223
Study 30793165 — intervention group
Group type: COMPARATOR
Intervention: Control IMF with small lipid droplets containing vegetable oils (n=108)
Number of subjects: 223
Study 29019177 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG+Canvaxin (BCG/Cv)
Number of subjects: 496
Study 29019177 — intervention group
Group type: COMPARATOR
Intervention: BCG+placebo (BCG/Pl)
Number of subjects: 496
Study 25341806 — intervention group
Group type: EXPERIMENTAL
Intervention: QUADRUPED (fQUAD1 and fQUAD2)
Number of subjects: 10
Study 25341806 — intervention group
Group type: EXPERIMENTAL
Intervention: MISSIONARY (fMISS1 and fMISS2)
Number of subjects: 10
Study 25341806 — intervention group
Group type: EXPERIMENTAL
Intervention: SIDELYING (fSIDE)
Number of subjects: 10
Study 25341806 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommended positions for female flexion-intolerant patients
Number of subjects: 10
Study 23077087 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine 20 mg/day
Number of subjects: 25
Study 23077087 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 21816845 — intervention group
Group type: EXPERIMENTAL
Intervention: 200-mg-bid celecoxib
Number of subjects: 1680
Study 21816845 — intervention group
Group type: EXPERIMENTAL
Intervention: 400-mg-bid celecoxib
Number of subjects: 1680
Study 21816845 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1680
Study 19415396 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral internal sphincterotomy (LIS)
Number of subjects: 62
Study 19415396 — intervention group
Group type: COMPARATOR
Intervention: Fissurectomy (F)
Number of subjects: 62
Study 18093337 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavior therapy (CBT) plus pill placebo
Number of subjects: 3
Study 18093337 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-behavior therapy (CBT) alone
Number of subjects: 3
Study 15075550 — intervention group
Group type: EXPERIMENTAL
Intervention: AIDSVAX B/E HIV vaccine trial
Number of subjects: 2545
Study 15075550 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial IDU
Number of subjects: 2545
Study 11594256 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol, bromocriptine, and tamoxifen
Number of subjects: 0
Study 11594256 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided aspiration
Number of subjects: 0
Study 11594256 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdochectomy
Number of subjects: 0
Study 11594256 — intervention group
Group type: EXPERIMENTAL
Intervention: Incision or aspiration with antibiotics
Number of subjects: 0
Study 9625213 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - 22.5 hours of specific communication training over 6 months
Number of subjects: 42
Study 9625213 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG) - 6 hours of standard medical education per week
Number of subjects: 42
Study 7881704 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (5 mg once daily)
Number of subjects: 11
Study 7881704 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (12.5 mg t.i.d.)
Number of subjects: 11
Study 7881704 — intervention group
Group type: COMPARATOR
Intervention: Enalapril and Captopril
Number of subjects: 11
Study 2974776 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorbinil (250 mg daily)
Number of subjects: 21
Study 2974776 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 2974776 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorbinil
Number of subjects: 21
Study 30099393 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneal ulcer prevention programme
Number of subjects: 24
Study 30099393 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 24
Study 27147450 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician-Supported Problem-Solving Bibliotherapy (CSPSB)
Number of subjects: 116